View Older Stories View More Recent Stories

Jan 5, 2023 04:00PM Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Dec 19, 2022 08:00AM Arcutis Submits Supplemental New Drug Application for ZORYVE® (roflumilast) Cream 0.3% for Expanded Indication for the Treatment of Plaque Psoriasis in Children Down to 2 Years of Age
Dec 19, 2022 08:00AM Arcutis Submits Supplemental New Drug Application for ZORYVE® (roflumilast) Cream 0.3% for Expanded Indication for the Treatment of Plaque Psoriasis in Children Down to 2 Years of Age
Dec 12, 2022 08:01AM Arcutis Biotherapeutics Inc. (ARQT) announced positive topline results from its INTEGUMENT-2 pivotal Phase 3 trial of roflumilast cream 0.15%
Dec 12, 2022 08:00AM Arcutis Announces Positive Topline Results from Second Atopic Dermatitis Pivotal Phase 3 Trial of Roflumilast Cream in Adults and Children Aged 6 and Older
Dec 12, 2022 08:00AM Arcutis Announces Positive Topline Results from Second Atopic Dermatitis Pivotal Phase 3 Trial of Roflumilast Cream in Adults and Children Aged 6 and Older
Dec 5, 2022 04:01PM Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Dec 5, 2022 08:00AM Arcutis Enrolls First Patient in Phase 1b Alopecia Areata Study Evaluating ARQ-255
Dec 5, 2022 08:00AM Arcutis Enrolls First Patient in Phase 1b Alopecia Areata Study Evaluating ARQ-255
Dec 1, 2022 03:00PM MyHealthTeam and Arcutis Biotherapeutics Launch New Social Network for People Living with Seborrheic Dermatitis
Nov 28, 2022 08:20AM Arcutis (ARQT) Says Study Showing Significant Improvements in Itch and Itch-Related Sleep Loss with Roflumilast Cream in Adults with Plaque Psoriasis Published in American Journal of Clinical Dermatol
Nov 28, 2022 08:00AM Study Showing Significant Improvements in Itch and Itch-Related Sleep Loss with Roflumilast Cream in Adults with Plaque Psoriasis Published in American Journal of Clinical Dermatology
Nov 28, 2022 08:00AM Study Showing Significant Improvements in Itch and Itch-Related Sleep Loss with Roflumilast Cream in Adults with Plaque Psoriasis Published in American Journal of Clinical Dermatology
Nov 21, 2022 09:15AM Arcutis Biotherapeutics Publishes First Environmental, Social, and Governance (ESG) Report
Nov 21, 2022 09:15AM Arcutis Biotherapeutics Publishes First Environmental, Social, and Governance (ESG) Report
Nov 17, 2022 08:01AM Arcutis Biotherapeutics' (ARQT) ZORYVE Cream 0.3% Added to Express Scripts, Inc.® National Formularies in the United States
Nov 17, 2022 08:00AM Arcutis’ ZORYVE® (Roflumilast) Cream 0.3% Added to Express Scripts, Inc.® National Formularies in the United States
Nov 17, 2022 08:00AM Arcutis’ ZORYVE® (Roflumilast) Cream 0.3% Added to Express Scripts, Inc.® National Formularies in the United States
Nov 15, 2022 11:09AM CORRECTION -- Arcutis Announces Positive Topline Results from INTEGUMENT-1 Pivotal Phase 3 Trial of Roflumilast Cream in Atopic Dermatitis in Adults and Children Aged Six Years and Older
Nov 15, 2022 11:09AM CORRECTION -- Arcutis Announces Positive Topline Results from INTEGUMENT-1 Pivotal Phase 3 Trial of Roflumilast Cream in Atopic Dermatitis in Adults and Children Aged Six Years and Older
Nov 15, 2022 08:02AM Arcutis Biotherapeutics (ARQT) Reports Positive Topline Results from INTEGUMENT-1 Pivotal Phase 3 Trial of Roflumilast Cream
Nov 15, 2022 08:01AM Arcutis Biotherapeutics (ARQT) Phase 3 Trial of Roflumilast Cream in Atopic Dermatitis in Adults and Children Aged Six Years and Older Met Its Primary Endpoint
Nov 15, 2022 08:00AM Arcutis Announces Positive Topline Results from INTEGUMENT-1 Pivotal Phase 3 Trial of Roflumilast Cream in Atopic Dermatitis in Adults and Children Aged Six Years and Older
Nov 15, 2022 08:00AM Arcutis Announces Positive Topline Results from INTEGUMENT-1 Pivotal Phase 3 Trial of Roflumilast Cream in Atopic Dermatitis in Adults and Children Aged Six Years and Older
Nov 11, 2022 08:00AM Arcutis to Present at Upcoming Investor Conference
Nov 8, 2022 04:02PM Arcutis Announces Third Quarter 2022 Financial Results and Provides Business Update
Nov 8, 2022 04:02PM Arcutis Announces Third Quarter 2022 Financial Results and Provides Business Update
Oct 25, 2022 04:05PM Arcutis to Report Third Quarter Financial Results
Oct 21, 2022 08:00AM Nationwide Seborrheic Dermatitis Survey Shows Burdensome and Lengthy Path to Diagnosis
Oct 21, 2022 08:00AM Nationwide Seborrheic Dermatitis Survey Shows Burdensome and Lengthy Path to Diagnosis
Oct 5, 2022 04:00PM Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Sep 26, 2022 08:02AM Arcutis Biotherapeutics Inc. (ARQT) Reports Positive Topline Results from ARRECTOR Pivotal Phase 3 Trial of Roflumilast
Sep 26, 2022 08:00AM Arcutis Announces Positive Topline Results from ARRECTOR Pivotal Phase 3 Trial of Roflumilast Foam 0.3% in Scalp and Body Psoriasis
Sep 26, 2022 08:00AM Arcutis Announces Positive Topline Results from ARRECTOR Pivotal Phase 3 Trial of Roflumilast Foam 0.3% in Scalp and Body Psoriasis
Sep 20, 2022 11:09AM Arcutis Biotherapeutics Inc. (ARQT) Announces Publication of Roflumilast Cream 0.3% Results from DERMIS-1 and -2 Phase 3 Trials in Plaque Psoriasis
Sep 20, 2022 11:07AM Journal of the American Medical Association Publishes Roflumilast Cream 0.3% Results from Pivotal DERMIS-1 and -2 Phase 3 Trials in Plaque Psoriasis
Sep 20, 2022 11:07AM Journal of the American Medical Association Publishes Roflumilast Cream 0.3% Results from Pivotal DERMIS-1 and -2 Phase 3 Trials in Plaque Psoriasis
Sep 9, 2022 08:15AM Arcutis Biotherapeutics (ARQT) Announces New Data from STRATUM Pivotal Phase 3 Trial of Roflumilast Foam 0.3% in Seborrheic Dermatitis Presented at EADV Congress
Sep 9, 2022 08:15AM New Data from Arcutis’ STRATUM Pivotal Phase 3 Trial of Roflumilast Foam 0.3% in Seborrheic Dermatitis Presented at European Academy of Dermatology and Venereology (EADV) Congress
Sep 9, 2022 08:15AM New Data from Arcutis’ STRATUM Pivotal Phase 3 Trial of Roflumilast Foam 0.3% in Seborrheic Dermatitis Presented at European Academy of Dermatology and Venereology (EADV) Congress
Sep 8, 2022 02:00AM LifeArc portfolio company Ducentis BioTherapeutics acquired by Arcutis Biotherapeutics for up to $400 million
Sep 7, 2022 05:00PM Arcutis Biotherapeutics Inc. (ARQT) Announces Acquisition of Ducentis BioTherapeutics Ltd.
Sep 7, 2022 05:00PM Arcutis Announces Acquisition of Ducentis BioTherapeutics Ltd.
Sep 7, 2022 05:00PM Arcutis Announces Acquisition of Ducentis BioTherapeutics Ltd.
Sep 6, 2022 08:00AM New Data from Arcutis’ Topical Roflumilast Clinical Program Presented at the European Academy of Dermatology and Venereology (EADV) Congress
Sep 6, 2022 08:00AM New Data from Arcutis’ Topical Roflumilast Clinical Program Presented at the European Academy of Dermatology and Venereology (EADV) Congress
Sep 2, 2022 04:00PM Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Sep 2, 2022 08:00AM Arcutis Biotherapeutics Inc. (ARQT) Appoints Neha Krishnamohan to its Board
Sep 2, 2022 08:00AM Arcutis Announces Appointment of Neha Krishnamohan to Board of Directors
Sep 2, 2022 08:00AM Arcutis Announces Appointment of Neha Krishnamohan to Board of Directors
View More Recent Stories View Older Stories